Incentive Structure for Innovations in the Chemical and Pharmaceutical Industry
Arguments and Positions
Maintaining its top position in research and development (R&D) is getting increasingly difficult for the industry location Germany. Emerging markets are catching up. Established industrial nations massively invest in education and research and create innovation-friendly framework conditions.
The German chemical-pharmaceutical industry is facing this challenge. In 2017, the industry invested about 10.8 billion euros in R&D and worked consistently on eliminating company-internal obstacles to innovation. But industry alone cannot defend Germany’s leading position – support from politics is needed for this purpose.
Provide research incentives
Funding for innovative companies and start-ups needs to be improved, mainly by means of investment-friendly framework conditions for venture capital.
Essential framework conditions for successful pharmaceutical research also include patent protection. When a new medicine is placed on the market, out of the 20 years of patent protection already many years have passed due to the long development process – so that only around 10 years of patent protection with market access would be left. With supplementary protection certificates (SPCs) the manufacturers can currently extend the patent term by maximally 5 years, making up for the long development times of medicines.
Backing from politicians and society
Innovative products and processes from chemistry and pharma are part of the solutions to the great societal challenges (healthcare, demographic change, food, mobility, climate protection, resources). Politicians and society should be open to innovation and thus facilitate progress.
Introduce an innovation check
Existing and future legislations should be checked as to their impacts on innovation.
- Increase spending, fiscal incentives for research and venture capital, reliable protection rights
The political goal of raising the share of R&D spending in GDP to 3.5 percent is positive. However, budget cuts 2020 for the federal research and education ministry (BMBF), as proposed by federal finance minister Scholz, are counterproductive to this. The framework conditions for research and innovation need to be improved – mainly by way of an adequate budget and fiscal incentives for research for all com¬panies. Furthermore, the framework conditions for venture capital should be optimised. Adequate patent terms, the possibility to use supplementary protection certificates and data protection are decisive for a reliable protection of intellectual property.
- Consistently continue the German High-Tech Strategy
Adequately funded R&D promotion programmes for a sufficiently wide range of technologies are impor-tant for maintaining the high level of research in Germany: in the energy sector, for more resource efficiency, health research and key technologies – such as new materials, catalysis, nano- and biotech-nology and the use of renewables. R&D promotion programmes need to take into account the specific needs of both SMEs and large companies.
- Introduce an "innovation check" in the impact assessment of legislation
Political framework conditions should not render innovations more difficult or even stand in their way. Instead, existing and future provisions should undergo an innovation check. This applies not onyl for new technologies but also, for example, for the circular economy and the enery transition (Energiewende).
- Strengthen natural science education, STEM subjects and university funding
General natural science-technical knowledge ("Sachkunde") should be introduced already in elementary schools, and one third of the total number of lessons in secondary schooling should be dedicated continually to STEM subjects. Excellent basic research is essential for the chemical-pharmaceutical industry. Universities should have more funding. Possibilities for further advanced education and qualification of employees need to be expanded.